. | Baseline (n = 119) . | 2-year follow-up (n = 119) . | P-value . |
---|---|---|---|
Clinical measures | |||
Tender joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | <0.001* |
Swollen joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | 0.005* |
Patient global (0–100), median (IQR) | 12 (4–25) | 13 (5–26) | 0.159 |
Patient pain (0–100), median (IQR) | 11 (3–20) | 11 (5–24) | 0.001* |
Physician global (0–100), median (IQR) | 0 (0–4) | 2 (0–6) | 0.003* |
CRP (mg/l), median (IQR) | 5 (2–6) | 4 (1–7) | 0.540 |
HAQ (0–3), median (IQR) | 0.2 (0.0–0.8) | 0.4 (0.0–0.9) | 0.285 |
DAS28-CRP, median (IQR) | 1.8 (1.6–2.1) | 1.9 (1.6–2.3) | 0.011* |
SDAI, median (IQR) | 2.2 (1.2–3.5) | 2.4 (1.3–5.0) | 0.011* |
CDAI, median (IQR) | 1.7 (0.6–3.0) | 2.0 (0.8–4.5) | 0.008* |
ACR/EULAR remission | 37% | 34% | 0.735 |
Radiographic measures | |||
TSS (0–448), median (IQR) | 14 (4–45) | 14 (3–47) | 0.451 |
JSN (0–84), median (IQR) | 9 (2–34) | 9 (2–34) | 0.513 |
X-ray erosion, median (IQR) | 3 (0–12) | 4 (0–13) | 0.402 |
Presence of X-ray erosion | 73% | 71% | 0.617 |
Ultrasound inflammatory measures | |||
Grey-scale sum score hands-only (0–30), median (IQR) | 2 (0–5) | 2 (1–5) | 0.229 |
Grey-scale sum score (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Doppler sum score hands-only (0–30), median (IQR) | 0 (0–1) | 0 (0–1) | 0.993 |
Doppler sum score (0–72), median (IQR) | 0 (0–2) | 0 (0–2) | 0.628 |
GLOESS hands-only (0–30), median (IQR) | 2 (0–5) | 3 (1–5) | 0.246 |
GLOESS (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Ultrasound strict remission, % | 8 | 4 | 0.267 |
Ultrasound semi-strict remission, % | 14 | 8 | 0.383 |
Ultrasound Doppler remission, % | 56 | 57 | 1 |
. | Baseline (n = 119) . | 2-year follow-up (n = 119) . | P-value . |
---|---|---|---|
Clinical measures | |||
Tender joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | <0.001* |
Swollen joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | 0.005* |
Patient global (0–100), median (IQR) | 12 (4–25) | 13 (5–26) | 0.159 |
Patient pain (0–100), median (IQR) | 11 (3–20) | 11 (5–24) | 0.001* |
Physician global (0–100), median (IQR) | 0 (0–4) | 2 (0–6) | 0.003* |
CRP (mg/l), median (IQR) | 5 (2–6) | 4 (1–7) | 0.540 |
HAQ (0–3), median (IQR) | 0.2 (0.0–0.8) | 0.4 (0.0–0.9) | 0.285 |
DAS28-CRP, median (IQR) | 1.8 (1.6–2.1) | 1.9 (1.6–2.3) | 0.011* |
SDAI, median (IQR) | 2.2 (1.2–3.5) | 2.4 (1.3–5.0) | 0.011* |
CDAI, median (IQR) | 1.7 (0.6–3.0) | 2.0 (0.8–4.5) | 0.008* |
ACR/EULAR remission | 37% | 34% | 0.735 |
Radiographic measures | |||
TSS (0–448), median (IQR) | 14 (4–45) | 14 (3–47) | 0.451 |
JSN (0–84), median (IQR) | 9 (2–34) | 9 (2–34) | 0.513 |
X-ray erosion, median (IQR) | 3 (0–12) | 4 (0–13) | 0.402 |
Presence of X-ray erosion | 73% | 71% | 0.617 |
Ultrasound inflammatory measures | |||
Grey-scale sum score hands-only (0–30), median (IQR) | 2 (0–5) | 2 (1–5) | 0.229 |
Grey-scale sum score (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Doppler sum score hands-only (0–30), median (IQR) | 0 (0–1) | 0 (0–1) | 0.993 |
Doppler sum score (0–72), median (IQR) | 0 (0–2) | 0 (0–2) | 0.628 |
GLOESS hands-only (0–30), median (IQR) | 2 (0–5) | 3 (1–5) | 0.246 |
GLOESS (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Ultrasound strict remission, % | 8 | 4 | 0.267 |
Ultrasound semi-strict remission, % | 14 | 8 | 0.383 |
Ultrasound Doppler remission, % | 56 | 57 | 1 |
P-values for differences between visits from modified Wilcoxon signed-rank test (Pratt method to handle ties) for numeric variables and McNemar’s test for binary variables; *P < 0.05.
CDAI: Clinical Disease Activity Index; GLOESS: Global OMERACT/EULAR ultrasound Synovitis Score; IQR: Interquartile Range; JSN: Joint Space Narrowing; SDAI: Simple Disease Activity Index; TSS: Total Sharp van der Heijde Score. Ultrasound strict remission: Grey-scale sum score equal to 0 and Doppler sum score equal to 0. Ultrasound semi-strict remission: Grey-scale sum score less than or equal to 1 and Doppler sum score equal to 0. Ultrasound Doppler remission: Doppler sum score equal to 0.
. | Baseline (n = 119) . | 2-year follow-up (n = 119) . | P-value . |
---|---|---|---|
Clinical measures | |||
Tender joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | <0.001* |
Swollen joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | 0.005* |
Patient global (0–100), median (IQR) | 12 (4–25) | 13 (5–26) | 0.159 |
Patient pain (0–100), median (IQR) | 11 (3–20) | 11 (5–24) | 0.001* |
Physician global (0–100), median (IQR) | 0 (0–4) | 2 (0–6) | 0.003* |
CRP (mg/l), median (IQR) | 5 (2–6) | 4 (1–7) | 0.540 |
HAQ (0–3), median (IQR) | 0.2 (0.0–0.8) | 0.4 (0.0–0.9) | 0.285 |
DAS28-CRP, median (IQR) | 1.8 (1.6–2.1) | 1.9 (1.6–2.3) | 0.011* |
SDAI, median (IQR) | 2.2 (1.2–3.5) | 2.4 (1.3–5.0) | 0.011* |
CDAI, median (IQR) | 1.7 (0.6–3.0) | 2.0 (0.8–4.5) | 0.008* |
ACR/EULAR remission | 37% | 34% | 0.735 |
Radiographic measures | |||
TSS (0–448), median (IQR) | 14 (4–45) | 14 (3–47) | 0.451 |
JSN (0–84), median (IQR) | 9 (2–34) | 9 (2–34) | 0.513 |
X-ray erosion, median (IQR) | 3 (0–12) | 4 (0–13) | 0.402 |
Presence of X-ray erosion | 73% | 71% | 0.617 |
Ultrasound inflammatory measures | |||
Grey-scale sum score hands-only (0–30), median (IQR) | 2 (0–5) | 2 (1–5) | 0.229 |
Grey-scale sum score (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Doppler sum score hands-only (0–30), median (IQR) | 0 (0–1) | 0 (0–1) | 0.993 |
Doppler sum score (0–72), median (IQR) | 0 (0–2) | 0 (0–2) | 0.628 |
GLOESS hands-only (0–30), median (IQR) | 2 (0–5) | 3 (1–5) | 0.246 |
GLOESS (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Ultrasound strict remission, % | 8 | 4 | 0.267 |
Ultrasound semi-strict remission, % | 14 | 8 | 0.383 |
Ultrasound Doppler remission, % | 56 | 57 | 1 |
. | Baseline (n = 119) . | 2-year follow-up (n = 119) . | P-value . |
---|---|---|---|
Clinical measures | |||
Tender joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | <0.001* |
Swollen joints count (0–28), median (IQR) | 0 (0–0) | 0 (0–0) | 0.005* |
Patient global (0–100), median (IQR) | 12 (4–25) | 13 (5–26) | 0.159 |
Patient pain (0–100), median (IQR) | 11 (3–20) | 11 (5–24) | 0.001* |
Physician global (0–100), median (IQR) | 0 (0–4) | 2 (0–6) | 0.003* |
CRP (mg/l), median (IQR) | 5 (2–6) | 4 (1–7) | 0.540 |
HAQ (0–3), median (IQR) | 0.2 (0.0–0.8) | 0.4 (0.0–0.9) | 0.285 |
DAS28-CRP, median (IQR) | 1.8 (1.6–2.1) | 1.9 (1.6–2.3) | 0.011* |
SDAI, median (IQR) | 2.2 (1.2–3.5) | 2.4 (1.3–5.0) | 0.011* |
CDAI, median (IQR) | 1.7 (0.6–3.0) | 2.0 (0.8–4.5) | 0.008* |
ACR/EULAR remission | 37% | 34% | 0.735 |
Radiographic measures | |||
TSS (0–448), median (IQR) | 14 (4–45) | 14 (3–47) | 0.451 |
JSN (0–84), median (IQR) | 9 (2–34) | 9 (2–34) | 0.513 |
X-ray erosion, median (IQR) | 3 (0–12) | 4 (0–13) | 0.402 |
Presence of X-ray erosion | 73% | 71% | 0.617 |
Ultrasound inflammatory measures | |||
Grey-scale sum score hands-only (0–30), median (IQR) | 2 (0–5) | 2 (1–5) | 0.229 |
Grey-scale sum score (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Doppler sum score hands-only (0–30), median (IQR) | 0 (0–1) | 0 (0–1) | 0.993 |
Doppler sum score (0–72), median (IQR) | 0 (0–2) | 0 (0–2) | 0.628 |
GLOESS hands-only (0–30), median (IQR) | 2 (0–5) | 3 (1–5) | 0.246 |
GLOESS (0–72), median (IQR) | 5 (2–9) | 7 (3–10) | 0.001* |
Ultrasound strict remission, % | 8 | 4 | 0.267 |
Ultrasound semi-strict remission, % | 14 | 8 | 0.383 |
Ultrasound Doppler remission, % | 56 | 57 | 1 |
P-values for differences between visits from modified Wilcoxon signed-rank test (Pratt method to handle ties) for numeric variables and McNemar’s test for binary variables; *P < 0.05.
CDAI: Clinical Disease Activity Index; GLOESS: Global OMERACT/EULAR ultrasound Synovitis Score; IQR: Interquartile Range; JSN: Joint Space Narrowing; SDAI: Simple Disease Activity Index; TSS: Total Sharp van der Heijde Score. Ultrasound strict remission: Grey-scale sum score equal to 0 and Doppler sum score equal to 0. Ultrasound semi-strict remission: Grey-scale sum score less than or equal to 1 and Doppler sum score equal to 0. Ultrasound Doppler remission: Doppler sum score equal to 0.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.